This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William J. McEntee, MD
Memory Assessment Clinics Inc 1217 East Ave S Sarasota, FL 34239

Robert G. Mair, PhD
Psychology Department University of New Hampshire Durham, NH 03824

Arch Gen Psychiatry. 1990;47(10):978.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In the July 1989 issue of the ARCHIVES, Martin et al¹ reported improvement of memory in patients with Korsakoff's psychosis (KP) by treatment with fluvoxamine maleate, a specific serotonin (5-HT) uptake inhibitor. This observation by itself is of interest, but the authors' interpretation of the data deserves comment.

Are data available showing the effects of fluvoxamine treatment on memory test performance and cerebrospinal fluid (CSF) levels of 5-hydroxyindoleacetic acid (5-HIAA) in normal persons?

The statistical analyses supporting the conclusions made for subjects with KP should be viewed with considerable caution. Three variables were analyzed: plasma levels of fluvoxamine, degree of improvement on tests of memory, and amount of reduction of CSF 5-HIAA. A total of 15 data points (5 for each variable) were reported; too few to provide a reliable multivariate analysis. Ideally, 20 data points per variable are needed for a sound multivariate analysis, and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?